tradingkey.logo

PREVIEW: Amgen dips with results due after the bell

ReutersFeb 3, 2026 7:34 PM

Amgen AMGN.O shares down 0.8% to $342 ahead of Q4 results due after the closing bell

Shares in obesity drugmakers declined on Tuersday after Novo Nordisk NOVOb.CO forecast a sharper than expected sales decline for 2026

Q4 adj. EPS expected at $4.73 on a 4.2% increase in revenue to $9.47 bln, per LSEG data, vs yr-ago results EPS of $4.73

The drugmaker has met or beaten EPS estimates in seven of past eight qtrs, with most recent miss in Q2 2024

Of the 35 analysts that cover Amgen Inc, the breakdown of recommendations are 17 "strong buy" or "buy," 15 "hold" and 3 "sell" or "strong sell" ratings

Median price target of $335 is up from $327.50 a month ago

AMGN shares up 4.2% YTD stock performance vs 1.7% gain in Dow Industrials .DJI

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI